Revance Therapeutics Inc. (RVNC) 32.34 $RVNC
Revance Appoints Mark A. Prygocki to Its Board of Directors
GlobeNewswire - Mon May 12, 9:25PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Mark A. Prygocki has been appointed to its Board of Directors and as the Chair of its Audit Committee, effective immediately.
Allergic Rhinitis Therapeutics Pipeline Review 2014 - Analysis of 35 Companies & 54 Drug Profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zkn5w5/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Genentech, Inc. - Nektar Therapeutics - BioTech Tools - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - ALK-Abello A/S - Mitsubishi Tanabe Pharma Corporation - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Revance Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Array BioPharma Inc. - Stallergenes S.A. - Cytos Biotechnology AG - Allergopharma Joachim Ganzer KG - Respiratorius AB - AnaptysBio, Inc. - Oxagen Limited - Axikin Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - Laboratorios LETI S.L. - Celsus Therapeutics Plc - KAEL-GemVax Co., Ltd. - GlycoMar Limited - Fountain Biopharma Inc. - Ampio Pharmaceuticals, Inc. - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/zk...c_rhinitis
Horizon Technology Finance Announces First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 3:24PM CDT
Horizon Technology Finance Corporation (Nasdaq:HRZN) (the "Company" or "Horizon"
, a leading specialty finance company that provides secured loans to venture capital and private equity-backed development-stage companies in the technology, life science, healthcare information and services, and cleantech industries, today announced its financial results for the first quarter ended March 31, 2014.
Biotech 101: Valuing Binary Events
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:18PM CDT
Binary events are the lifeblood of investing in biotech companies. A clinical trial result or Food and Drug Administration decision can send the company's value up or down considerably. And not necessarily the same amount in either direction; the...
Revance Therapeutics to Release First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 13, 2014
GlobeNewswire - Tue Apr 29, 3:04PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release first quarter 2014 financial results on Tuesday, May 13, 2014 after the close of market. Revance will host a conference call and a live Internet webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business and clinical update.
PharmaPoint: Migraine - Current and Future Players 2014
M2 - Tue Apr 29, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5djb5h/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Current and Future Players" report to their offering. PharmaPoint: Migraine - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Migraine Market. The report identifies and analyses the key companies shaping and driving the global Migraine market. The report provides insight into the competitive Migraine landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for Migraine - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Migraine sector through market impact analysis, future market scenario and company analysis Key Topics Covered: - Tables & Figures - Introduction - Market Outlook - Current and Future Players - GlaxoSmithKline - AstraZeneca - Merck - Vernalis - Almirall - Pfizer - Zogenix - NuPathe - Allergan - RedHill Biopharma - OptiNose - CoLucid Pharmaceuticals - SUDA - Revance Therapeutics - NeurAxon For more information visit http://www.researchandmarkets.com/research/5d...harmapoint
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
This Week in Biotech: Is This the Return of Big M&A?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 26, 2:15PM CDT
With the SPDR S&P Biotech Index up 18% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Top Gainers Technical Coverage -- Research on Bitauto Holdings, Intrexon, MoneyGram Intl., and Revance Therapeutics
PR Newswire - Wed Apr 23, 11:54AM CDT
On Tuesday, April 22, 2014, the NASDAQ Composite ended at 4,161.46, up 0.97%, the Dow Jones Industrial Average finished the session 0.40% higher at 16,514.37, and the S&P 500 closed at 1,879.55, up 0.41%. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Bitauto Holdings Ltd (NYSE: BITA), Intrexon Corp. (NYSE: XON), MoneyGram International Inc. (NASDAQ: MGI) and Revance Therapeutics Inc. (NASDAQ: RVNC). Free technical research on BITA, XON, MGI and RVNC can be downloaded upon signing up at:
Revance Therapeutics (RVNC) Soars: Stock Up 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:39AM CDT
Revance Therapeutics, Inc. was a big mover last session, as its shares rose nearly 26% on the day.
Why GW Pharmaceuticals, Revance Therapeutics, and Allergan Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 4:15PM CDT
The health-care sector may have been a major crutch for the broad-based S&P 500 during the past two months, but today it was its greatest savior, with merger and acquisition activity galore driving the index to the upside. Also helping...
Why Revance Therapeutics Inc. Shares Are Sitting Pretty
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 11:45AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Revance Therapeutics , a clinical-stage...
Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines
GlobeNewswire - Mon Apr 21, 3:55PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines. RT002 is Revance's proprietary, injectable botulinum toxin investigational product that incorporates the patented TransMTS(R) technology and is designed to provide a longer lasting duration of effect. In the study, RT002 met its primary efficacy and safety endpoints. The open-label, dose escalating, Phase 1/2 study enrolled 48 adults in four cohorts. All subjects had Severe or Moderate wrinkles at baseline, measured using the 4-point Global Line Severity Scale (GLSS). In summary, the data showed:
Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014
Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexes
GlobeNewswire - Mon Mar 31, 7:00PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000(R) and Russell 3000(R) Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014.
Revance Therapeutics Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook
GlobeNewswire - Wed Mar 26, 3:01PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), today reported financial results for the three and twelve months ended December 31, 2013.
Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Revance Therapeutics to Release Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Wednesday, March 26, 2014
GlobeNewswire - Wed Mar 12, 3:01PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release fourth quarter and full year 2013 financial results on Wednesday, March 26, 2014 after the close of market. Revance will host a conference call and a live Internet webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business update.
Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 3:28PM CST
The beginning of the year swoon has decisively been put in the rearview mirror, with the broad-based S&P 500 launching itself to a new all-time high earlier this week on easing geopolitical fears. For skeptics like me, that's an opportunity to...
Revance Appoints Mark A. Prygocki to Its Board of Directors
GlobeNewswire - Mon May 12, 9:25PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Mark A. Prygocki has been appointed to its Board of Directors and as the Chair of its Audit Committee, effective immediately.
Allergic Rhinitis Therapeutics Pipeline Review 2014 - Analysis of 35 Companies & 54 Drug Profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zkn5w5/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Genentech, Inc. - Nektar Therapeutics - BioTech Tools - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - ALK-Abello A/S - Mitsubishi Tanabe Pharma Corporation - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Revance Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Array BioPharma Inc. - Stallergenes S.A. - Cytos Biotechnology AG - Allergopharma Joachim Ganzer KG - Respiratorius AB - AnaptysBio, Inc. - Oxagen Limited - Axikin Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - Laboratorios LETI S.L. - Celsus Therapeutics Plc - KAEL-GemVax Co., Ltd. - GlycoMar Limited - Fountain Biopharma Inc. - Ampio Pharmaceuticals, Inc. - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/zk...c_rhinitis
Horizon Technology Finance Announces First Quarter 2014 Financial Results
GlobeNewswire - Tue May 06, 3:24PM CDT
Horizon Technology Finance Corporation (Nasdaq:HRZN) (the "Company" or "Horizon"
, a leading specialty finance company that provides secured loans to venture capital and private equity-backed development-stage companies in the technology, life science, healthcare information and services, and cleantech industries, today announced its financial results for the first quarter ended March 31, 2014. Biotech 101: Valuing Binary Events
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:18PM CDT
Binary events are the lifeblood of investing in biotech companies. A clinical trial result or Food and Drug Administration decision can send the company's value up or down considerably. And not necessarily the same amount in either direction; the...
Revance Therapeutics to Release First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 13, 2014
GlobeNewswire - Tue Apr 29, 3:04PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release first quarter 2014 financial results on Tuesday, May 13, 2014 after the close of market. Revance will host a conference call and a live Internet webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business and clinical update.
PharmaPoint: Migraine - Current and Future Players 2014
M2 - Tue Apr 29, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5djb5h/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Current and Future Players" report to their offering. PharmaPoint: Migraine - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Migraine Market. The report identifies and analyses the key companies shaping and driving the global Migraine market. The report provides insight into the competitive Migraine landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry experts. Scope - Investigation of current and future market competition for Migraine - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Migraine sector through market impact analysis, future market scenario and company analysis Key Topics Covered: - Tables & Figures - Introduction - Market Outlook - Current and Future Players - GlaxoSmithKline - AstraZeneca - Merck - Vernalis - Almirall - Pfizer - Zogenix - NuPathe - Allergan - RedHill Biopharma - OptiNose - CoLucid Pharmaceuticals - SUDA - Revance Therapeutics - NeurAxon For more information visit http://www.researchandmarkets.com/research/5d...harmapoint
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
This Week in Biotech: Is This the Return of Big M&A?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 26, 2:15PM CDT
With the SPDR S&P Biotech Index up 18% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Top Gainers Technical Coverage -- Research on Bitauto Holdings, Intrexon, MoneyGram Intl., and Revance Therapeutics
PR Newswire - Wed Apr 23, 11:54AM CDT
On Tuesday, April 22, 2014, the NASDAQ Composite ended at 4,161.46, up 0.97%, the Dow Jones Industrial Average finished the session 0.40% higher at 16,514.37, and the S&P 500 closed at 1,879.55, up 0.41%. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Bitauto Holdings Ltd (NYSE: BITA), Intrexon Corp. (NYSE: XON), MoneyGram International Inc. (NASDAQ: MGI) and Revance Therapeutics Inc. (NASDAQ: RVNC). Free technical research on BITA, XON, MGI and RVNC can be downloaded upon signing up at:
Revance Therapeutics (RVNC) Soars: Stock Up 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:39AM CDT
Revance Therapeutics, Inc. was a big mover last session, as its shares rose nearly 26% on the day.
Why GW Pharmaceuticals, Revance Therapeutics, and Allergan Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 4:15PM CDT
The health-care sector may have been a major crutch for the broad-based S&P 500 during the past two months, but today it was its greatest savior, with merger and acquisition activity galore driving the index to the upside. Also helping...
Why Revance Therapeutics Inc. Shares Are Sitting Pretty
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 11:45AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Revance Therapeutics , a clinical-stage...
Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines
GlobeNewswire - Mon Apr 21, 3:55PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines. RT002 is Revance's proprietary, injectable botulinum toxin investigational product that incorporates the patented TransMTS(R) technology and is designed to provide a longer lasting duration of effect. In the study, RT002 met its primary efficacy and safety endpoints. The open-label, dose escalating, Phase 1/2 study enrolled 48 adults in four cohorts. All subjects had Severe or Moderate wrinkles at baseline, measured using the 4-point Global Line Severity Scale (GLSS). In summary, the data showed:
Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014
Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexes
GlobeNewswire - Mon Mar 31, 7:00PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000(R) and Russell 3000(R) Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014.
Revance Therapeutics Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook
GlobeNewswire - Wed Mar 26, 3:01PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), today reported financial results for the three and twelve months ended December 31, 2013.
Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Revance Therapeutics to Release Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Wednesday, March 26, 2014
GlobeNewswire - Wed Mar 12, 3:01PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release fourth quarter and full year 2013 financial results on Wednesday, March 26, 2014 after the close of market. Revance will host a conference call and a live Internet webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business update.
Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 3:28PM CST
The beginning of the year swoon has decisively been put in the rearview mirror, with the broad-based S&P 500 launching itself to a new all-time high earlier this week on easing geopolitical fears. For skeptics like me, that's an opportunity to...
